Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01202708 · ClinicalTrials.gov registry record · NA
Gambro AK200 ULTRA Hemodiafiltration Study
A NA study of Chronic Renal Failure, sponsored by Vantive Health.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT01202708: Completed NA study of Chronic Renal Failure, sponsored by Vantive Health.
NCT01202708 is a NA study of Chronic Renal Failure that has completed, run by Vantive Health. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01202708, a NA study of Chronic Renal Failure, has completed, sponsored by Vantive Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to assess the safety, efficacy and dialytic capabilities of hemodiafiltration with on-line prepared substitution fluid using the AK200 ULTRA in comparison to conventional hemodialysis.
Conditions Studied
Interventions
- DEVICE On line hemofiafiltration
- DEVICE On line hemodiafiltration
Study Locations (1)
District of Columbia
- George Washington University Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 1997-08 |
| Phase | NA |
What the finished NCT01202708 record still lists
NCT01202708 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Chronic Renal Failure appearing as the primary indexed condition, and to 2 interventions - of which On line hemofiafiltration is the first listed.
NCT01202708 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT01202708 about?
NCT01202708 is a clinical study titled "Gambro AK200 ULTRA Hemodiafiltration Study". This study is designed to assess the safety, efficacy and dialytic capabilities of hemodiafiltration with on-line prepared substitution fluid using the AK200 ULTRA in comparison to conventional hemodialysis.
What is the current status of trial NCT01202708?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 1997-08.
What conditions does trial NCT01202708 study?
This clinical trial studies the following conditions: Chronic Renal Failure.
What interventions are being tested in trial NCT01202708?
The interventions under investigation include: On line hemofiafiltration (DEVICE), On line hemodiafiltration (DEVICE).
Who is sponsoring clinical trial NCT01202708?
This trial is sponsored by Vantive Health, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01202708 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Renal Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01202708's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia